沙格司亭sargramostim（商标名 Leukine）原研参比剂，美国产品，平价供应
产品名称：沙格司亭

英文名称：Leukine（sargramostim）

原研厂家：SANOFI-AVENTIS

上市地区：美国
规格
LEUKINE 250MCG SDV PWD 5/PAC  SARGRAMOSTIM  SANOFI-AVENTIS  00024-5843-05
LEUKINE SDV PWD 250MCG 5  SARGRAMOSTIM  SANOFI U.S. LLC  00024-5843-05            
Leukine(Sargramostim)
LEUKINE Rx
Generic Name and Formulations:
Sargramostim (recombinant human granulocyte-macrophage colony stimulating factor, or rhu GM-CSF) 250mcg; per vial; pwd for SC inj or IV infusion after reconstitution; preservative-free.
Company:
Sanofi Genzyme Company
Select therapeutic use: White blood cell disorders
Indications for LEUKINE:
To speed neutrophil recovery and reduce infections after induction chemotherapy in treatment of acute myelogenous leukemia (AML) in patients >55 years of age. To mobilize hematopoietic progenitor cells into peripheral blood for collection by leukapheresis. To speed myeloid recovery in non-Hodgkin's lymphoma, acute lymphoblastic leukemia (ALL), and Hodgkin's disease in autologous bone marrow transplantation (BMT). To speed myeloid recovery in allogeneic BMT. Patients with BMT failure or engraftment delay.
Adult:
See full labeling for timing and duration of dosing, and for repeat courses of therapy. Individualize. Neutrophil recovery: 250mcg/m2 per day IV over 4 hrs. Mobilization or post peripheral blood progenitor cell transplantation: 250mcg/m2 per day IV over 24 hrs or SC once daily. Myeloid recovery after BMT: 250mcg/m2 per day IV over 2 hrs. BMT failure or engraftment delay: 250mcg/m2 per day IV over 2 hrs for 14 days.
Children:
See full labeling.
Contraindications:
Excessive leukemic myeloid blasts in bone marrow or peripheral blood (≥10%). Allergy to GM-CMF or yeast-derived products. Concomitant (within 24 hrs) chemotherapy or radiotherapy.
Warnings/Precautions:
Fluid retention, pleural or pericardial effusions. Pulmonary infiltrates. Respiratory disease or symptoms. Hypoxia. Reduce infusion rate by ½ if dyspnea occurs; discontinue if dyspnea worsens. Cardiac disease. CHF. Renal or hepatic dysfunction (monitor before and every other week during therapy). Monitor CBC and differential twice weekly. Reduce dose by ½ or discontinue if absolute neutrophil count exceeds 20,000cells/mm3 or if platelet count exceeds 500,000cells/mm3. Use for shortest duration required. Myeloid malignancies. Monitor body weight and hydration. Pregnancy (Cat.C). Nursing mothers.
Interactions:
Caution with lithium, corticosteroids, others that may enhance myeloproliferative effects. May be antagonized by radiotherapy, myelotoxic drugs.
Pharmacological Class:
Granulocyte-macrophage colony stimulating factor (recombinant).
Adverse Reactions:
Flu-like symptoms, GI disturbances, edema, dyspnea, pharyngitis, rash, joint or bone or chest pain, eye hemorrhage, hypomagnesemia, anxiety, headache, pleural +/or pericardial effusion, arthralgia, myalgia, others.
How Supplied:
Vials—5